NLRP3 and Left ventricular dilatation: In this model, additional deletion of NLRP3 or pharmacologic inhibition of IL-1β signaling using the IL-1-receptor antagonist significantly reduced left ventricular dilatation and abrogated the progressive decrease in fractional shortening (FS) observed in wildtype and saline treated mice, thus implicating the NLRP3 inflammasome in this cardiac dysfunction (88).